4
Changes in Ownership
Janux Therapeutics, Inc. Filed Acc 0001415889-24-025792
President and CEO sold 25,000 shares at an average $53.54 ($1,338,559)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Campbell David Alan · President and CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-10-28 | Sale : show line 1 in the form 10b5-1 | −13,897 | $53.22 | $739,650 | 293,157 | D |
| 2024-10-28 | Sale : show line 2 in the form 10b5-1 | −11,103 | $53.94 | $598,909 | 282,054 | D |
| Open-market sales · 25,000 sh · avg $53.54 · $1,338,559 | ||||||
Loading xslF345X05/form4-10302024_071002.xml…